¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"stop action imaging"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • gestagenic action
    ÇÁ·Î°Ô½ºÅ×·ÐÀÛ¿ë, Ȳüȣ¸£¸óÀÛ¿ë
  • immediate action
    Áï½ÃÀÛ¿ë
  • inhibitory action
    ¾ïÁ¦ÀÛ¿ë, ÀúÁöÀÛ¿ë
  • inotropic action
    ¼öÃàÃËÁøÀÛ¿ë
  • interferential action
    °£¼·ÀÛ¿ë
  • monophasic action potential
    ´Ü»óȰµ¿ÀüÀ§
  • mass action
    Áú·®ÀÛ¿ë
  • nerve action potential
    ½Å°æÈ°µ¿ÀüÀ§
  • neurotropic action
    Çâ½Å°æÀÛ¿ë
  • photochemical action
    ±¤È­ÇÐÀÛ¿ë
  • polyphasic action potential
    ´Ù»óȰµ¿ÀüÀ§
  • primary action
    ÀÏÂ÷ÀÛ¿ë
  • promotor action
    ÃËÁøÀÛ¿ë
  • pharmacological action
    ¾à¸®ÀÛ¿ë
  • reflex action
    ¹Ý»çÀÛ¿ë
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • inotropic action
    ¼öÃàÃËÁøÀÛ¿ë
  • interferential action
    °£¼·ÀÛ¿ë
  • mass action
    Áú·®ÀÛ¿ë
  • neurotropic action
    Çâ½Å°æÀÛ¿ë
  • pharmacological action
    ¾à¸®ÀÛ¿ë
  • photochemical action
    ±¤È­ÇÐÀÛ¿ë
  • primary action
    ÀÏÂ÷ÀÛ¿ë, ÀÏÂ÷±â´É
  • promotor action
    ÃËÁøÀÛ¿ë
  • reflex action
    ¹Ý»çÀÛ¿ë
  • specific action
    ƯÀÌÀÛ¿ë
  • synergistic action
    »ó½ÂÀÛ¿ë
  • thermogenic action
    ¹ß¿­ÀÛ¿ë
  • trigger action
    ¹æ¾Æ¼èÀÛ¿ë, À¯¹ßÀÛ¿ë
  • biphasic action potential
    ÀÌ»óȰµ¿ÀüÀ§
  • compound muscle action potential
    (¢¡muscle) º¹ÇÕ±ÙȰµ¿ÀüÀ§
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • inotropic action
    º¯·ÂÀÛ¿ë(ܨÕôíÂéÄ), ¼öÃàÃËÁøÀÛ¿ë(â¥õêõµòäíÂéÄ).³»°ú¼öÃà·Â
  • inotropic action
    º¯·ÂÀÛ¿ë, ¼öÃàÃËÁøÀÛ¿ë.[³»°ú]¼öÃà·Â º¯µ¿ÀÛ¿ë.
  • pharmacodynamic action
    ¾à¿ªÇÐ(Àû) ÀÛ¿ë(å·æ³ùÊ(îÜ) íÂéÄ).
  • photochemical action
    ±¤È­ÇÐÀÛ¿ë(ÊÙËöËí).
  • photodynamic action
    ±¤¿ªÇÐÀÛ¿ë(ÎÃæ³ùÊ íÂéÄ).
  • physical action
    ¹°¸®Àû ÀÛ¿ë(¡­íÂéÄ).
  • physiological action
    »ý¸®ÀÛ¿ë(¡­íÂéÄ).
  • primary action
    ÀÏÂ÷±â´É
  • principle of least action
    ÃÖ¼ÒÀÛ¿ëÀÇ ¿ø¸®(õÌá´íÂéÄ¡­ê«ìµ).
  • prolonged action drug
    Áö¼Ó¼º ¾àÁ¦(ò¥áÙàõå·ð¥).
  • prolonged action drug
    Ưȿ¼º ¾àÁ¦(÷åüùàõå·ð¥), Áö¼Ó¼º ¾àÁ¦(ò¥áÙàõå·ð¥).
  • promotor action
    ÃËÁøÀÛ¿ë.
  • protoplasmic action
    ¿øÇüÁúÀÛ¿ë(¡­íÂéÄ).
  • reflex action
    ¹Ý»çÀÛ¿ë.
  • remote action
    ¿ø°ÝÀÛ¿ë(êÀ̰íÂéÄ).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • partial echo imaging
    ºÎºÐ ¿¡ÄÚ ¿µ»ó
  • partial volume imaging
    ºÎºÐ ¿ëÀû ¿µ»ó
  • perfusion and diffusion imaging
    °ü·ù È®»ê ¿µ»ó
  • perfusion imaging
    °ü·ù ¿µ»ó
  • phase offset multiplannar (POMP) imaging
    À§»ó ¿ÀÇÁ¼Â ´Ù¸é ¿µ»ó
  • radionuclide imaging
    ¹æ»ç¼º ÇÙÁ¾À̸ÞÀÌ¡.
  • real time imaging
    ½Ç½Ã°£ ¿µ»ó ±â¹ý
  • receptor imaging
    ¼ö¿ëü¿µ»ó(È­)
  • spin echo (SE) imaging
    ½ºÇÉ ¿¡ÄÚ ¿µ»ó
  • spin echo intravoxel incoherent motion imaging
    ½ºÇÉ¿¡ÄÚ È­Àû¼Ò³» ºñ°áÁý ¿îµ¿ ¿µ»ó¼ú
  • spin warp imaging
    ½ºÇÉ ±ÁÈû ¿µ»ó
  • ultrasonic imaging
    ÃÊÀ½ÆÄ¿µ»ó
  • velocity imaging
    ¼Óµµ ¿µ»ó
  • absorption action
    Èí¼öÀÛ¿ë.
  • action myoclonia
    Ȱµ¿°£´ë¼º ±Ù°æ·Ã(Áõ)(¡­ÊàÓÛàõÐÉÌâÕýñø)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • spin warp imaging
    ½ºÇɱÁÈû¿µ»ó
  • T1 weighted FLASH imaging
    T1°­Á¶FLASH¿µ»ó
  • ultrasonic imaging
    ÃÊÀ½ÆÄ¿µ»ó
  • velocity imaging
    ¼Óµµ¿µ»ó
  • Zebra-stripe imaging method
    ¾ó·è¸»¹«´Ì¿µ»ó¹æ¹ý
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
CSI calculus surface index; cancer serum index; cavernous sinus infiltration; cervical spine injury; che...
DI date of injury; defective interfering [particle]; dentinogenesis imperfecta; deoxyribonucleic acid i...
DICOM digital imaging and communication in medicine
DTIA Doppler tissue imaging acceleration
DTIE Doppler tissue imaging energy
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
MUAP Motor Unit Action Potential
MAP muscle action potential
NAP Nerve action potential
PAR Participatory Action Research
SNAP Sensory Nerve Action Potential
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • dynamic action
    µ¿·Â ÀÛ¿ë
  • electrolytic action
    ÀüÇØ ÀÛ¿ë
  • fungicidal action
    »ìÁø±Õ ÀÛ¿ë
  • hemostatic action
    ÁöÇ÷ ÀÛ¿ë
    ÃâÇ÷À» ¸ØÃß°Ô ÇÏ´Â ÀÛ¿ë. ÈçÈ÷ 'ÁöÇ÷'À̶ó ºÎ¸¥´Ù.
  • hormone like action
    È£¸£¸ó À¯»ç ÀÛ¿ë
    ü³»¿¡ µé¾î¿Í È£¸£¸ó°ú ºñ½ÁÇÑ ¿ªÇÒÀ» ÇÏ´Â °Í.
  • immediate action
    Áï°¢ ÀÛ¿ë
  • least action
    ÃÖ¼Ò ÀÛ¿ë
  • nicotinic action
    ´ÏÄÚÆ¾ ÀÛ¿ë
  • onset of action
    ÀÛ¿ë½ÃÀÛ
  • permissive action
    Çã¿ë ÀÛ¿ë
  • pharmacological action
    ¾à¸® ÀÛ¿ë
  • physiological action
    »ý¸® ÀÛ¿ë
  • presynaptic inhibitory action
    ½Ã³³½ºÀü ¾ïÁ¦ ÀÛ¿ë
  • reflex action
    ¹Ý»ç Ȱµ¿
  • reverse action
    ¹Ý´ë ÀÛ¿ë
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 6 ÆäÀÌÁö: 5
thyroid imaging <radiology> Tc-99m pertechnetate 6 mCi, I-123 sodium iodide 200 - 400 uCi PO
(12 Dec 1998)
transfer imaging The production of an ultrasound image by detection and analysis of sound on the opposite side of the body from the emitting transducer.
Synonym: through transfer imaging.
(05 Mar 2000)
ultrasound imaging <investigation, procedure> A technique in which high-frequency sound waves are bounced off internal organs and the echo pattern is converted into a 2 dimensional picture of the structures beneath the transducer.
(12 May 1997)
kidney: gallium imaging <radiology> 10-20% of Ga-67 excreted via GU tract; no renal activity after 24hrs abnormal uptake (images at 48-72 hrs): tumour, primary renal tumour (variable uptake), lymphoma/leukaemia, metastases (e.g., melanoma), inflammation, acute pyelonephritis (88% sensitivity); abscess, lobar nephroma, others, collagen vascular disease, vasculitis, Wegener granulomatosis, amyloidosis, haemochromatosis, hepatic failure, antineoplastic drugs, transplant rejection: acute, chronic, ATN see also: gallium: indications
(12 Dec 1998)
liver metastases: ultrasound imaging <radiology> Echogenic (25%), colonic carcinoma, hepatocellular carcinoma, treated breast carcinoma mixed echogenicity (37.5%), breast carcinoma, rectal carcinoma, lung carcinoma, stomach carcinoma, anaplastic cancer, cervical carcinoma, carcinoid hypoechoic (37.5%), lymphoma, pancreatic carcinoma, cervical carcinoma, lung carcinoma (adenocarcinoma), nasopharyngeal carcinoma see: liver metastases
(12 Dec 1998)
lung: gallium imaging <radiology> Scans at 48 hrs because 50% of normals show activity at 24 hrs, focal uptake, primary pulmonary malignancy, benign disorder: granuloma, abscess, pneumonia, silicosis, multifocal/diffuse uptake, infection, TB: active lesion, miliary TB, rapidly progressive TB pneumonia, PCP: unimpressive symptoms and CXR, CMV, inflammation: sarcoid, interstitial lung disease (pneumoconiosis, idiopathic pulmonary fibrosis, lymphangitic carcinomatosis), radiation pneumonitis, drugs: bleomycin, amiodarone, contrast lymphangiography (in 50%) see: gallium: indications, uptake with normal chest film
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
ÅëÇÕ°Ë»ö ¿Ï·á